Price T Rowe Associates Inc. MD grew its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 2.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,036,412 shares of the biopharmaceutical company's stock after purchasing an additional 107,350 shares during the period. Price T Rowe Associates Inc. MD owned about 5.77% of Xencor worth $92,758,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of XNCR. Tower Research Capital LLC TRC boosted its stake in Xencor by 132.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,865 shares of the biopharmaceutical company's stock worth $181,000 after buying an additional 4,482 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in shares of Xencor by 16.9% in the 4th quarter. MetLife Investment Management LLC now owns 40,740 shares of the biopharmaceutical company's stock worth $936,000 after acquiring an additional 5,888 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Xencor by 7.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,501,532 shares of the biopharmaceutical company's stock valued at $34,509,000 after purchasing an additional 102,297 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in shares of Xencor by 11.0% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 83,535 shares of the biopharmaceutical company's stock valued at $1,918,000 after purchasing an additional 8,290 shares during the last quarter. Finally, Barclays PLC raised its position in Xencor by 112.6% in the 4th quarter. Barclays PLC now owns 330,745 shares of the biopharmaceutical company's stock worth $7,600,000 after purchasing an additional 175,177 shares during the period.
Xencor Trading Down 3.0 %
XNCR opened at $10.51 on Monday. The firm has a market capitalization of $740.56 million, a price-to-earnings ratio of -3.28 and a beta of 0.90. Xencor, Inc. has a one year low of $7.16 and a one year high of $27.24. The business has a 50 day simple moving average of $11.77 and a two-hundred day simple moving average of $18.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.
Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping analysts' consensus estimates of ($0.81) by $0.19. The company had revenue of $52.79 million during the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. Analysts predict that Xencor, Inc. will post -3.68 EPS for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on XNCR shares. Wells Fargo & Company reduced their price objective on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. StockNews.com lowered Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. Finally, William Blair started coverage on Xencor in a research note on Monday, April 21st. They issued an "outperform" rating on the stock. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $33.86.
Get Our Latest Research Report on Xencor
Xencor Profile
(
Free Report)
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Further Reading
Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Xencor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.
While Xencor currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
